217099-14-4

Usage

Uses

Used in Pharmaceutical Industry:
CYCLO(-ARG-GLY-ASP-D-TYR-LYS) is used as a potential antimicrobial and antiviral agent for its ability to target and combat various pathogens, offering a new approach to treating infections.
Used in Drug Development:
CYCLO(-ARG-GLY-ASP-D-TYR-LYS) is utilized as a candidate for drug development due to its increased stability and resistance to enzymatic degradation, which may lead to more effective and longer-lasting therapeutic agents.
Used in Biomedical Research:
CYCLO(-ARG-GLY-ASP-D-TYR-LYS) serves as a valuable tool in biomedical research for its capacity to modulate biological pathways and target specific protein-protein interactions, aiding in the understanding of complex disease mechanisms and the development of novel therapeutic strategies.

Upstream product

• 204777-78-6 Fmoc-Lys(ivDde)-OH 

Downstream Products

• 1421230-96-7 C₃₀H₄₁N₉O₉ 
• 1430747-19-5 C₂₇H₄₀IN₉O₈ 
• 1455009-92-3 cyclo[Arg-Gly-Asp-D-Tyr-Lys(Trp)] 
• 1454884-91-3 cyclo[Arg-Gly-Asp-D-Tyr-Lys(Trp)] monohydrochloride 
• 1454884-93-5 cyclo[Arg-Gly-Asp-D-Tyr-Lys(Boc-Tpi)] 
• 1454884-92-4 cyclo[Arg-Gly-Asp-D-Tyr-Lys(Boc-Trp)] 
• 1380037-49-9 C₄₅H₇₅N₉O₉ 
• 1226778-21-7 cyclo(RGDyK)SH 

Relevant academic research and scientific papers

Comparison of radioiodine- or radiobromine-labeled rgd peptides between direct and indirect labeling methods

Radiolabeled cyclic peptides containing the (Arg-Gly-Asp) RGD sequence for use in positron emission tomography (PET) imaging, single-photon emission computed tomography (SPECT) imaging, and targeted radionuclide therapy of cancer have been reported. In this study, RGD was used as a model carrier peptide for diagnosis and therapy of cancer. To evaluate the characteristics of radiohalogen-labeled peptides, several kinds of labeled RGD peptides [125I-c(RGDyK), 77Br-c(RGDyK), [125I]SIB-c(RGDfK), [77Br]SBrB-c(RGDfK), [125I]SIB-EG2-c(RGDfK), and [77Br]SBrB-EG2-c(RGDfK)] were designed, prepared, and evaluated. In these initial studies, 77Br (t1/2=57.0h) and 125I (t1/2=59.4d) were used because of their longer half-lives. Precursor peptides were synthesized using a standard 9-fluorenylmethyloxycarbonyl (Fmoc)-based solid-phase methodology. Radiolabeled peptides were prepared by chloramine-T method or conjugation of RGD peptides with [125I]N-succinimidyl 3-iodobenzoate ([125I]SIB) or [77Br]N-succinimidyl 3-bromobenzoate ([77Br]SBrB). Measurement of the partition coefficients, integrin binding assay, and biodistribution experiments in tumor-bearing mice were performed. 125I and 77Br labeling were successfully performed using similar methods, and in vitro characteristics and biodistributions were similar between the 125I-labeled and corresponding 77Br-labeled peptides. [125I]SIB- and [77Br]SBrB-conjugated RGD peptides showed higher partition coefficients, lower tumor uptakes, and higher intestinal uptake than 125I-c(RGDyK) and 77Br-c(RGDyK). [125I]SIB-EG2-c(RGDfK) and [77Br]SBrB-EG2-c(RGDfK), which possess an ethylene glycol linker, decreased lipophilicity and uptake in intestine compared with [125I]SIB-c(RGDfK) and [77Br]SBrB-c(RGDfK), which possess no linker. However, the improvement in biodistribution of [125I]SIB-EG2-c(RGDfK) and [77Br]SBrB-EG2-c(RGDfK)] was insufficient. In conclusion, directly radiohalogenated c(RGDyK) peptides are potentially more useful for tumor imaging and therapy than indirectly radiohalogenated ones.

Solid-phase synthesis and fluorine-18 radiolabeling of cycloRGDyK

Solid-phase peptide synthesis, head-to-tail cyclization, and subsequent radiolabeling provided a reproducible, simple, rapid synthetic method to generate the cyclic peptide radiotracer cRGDyK([18F]FBA). Herein is reported the first on-resin cyclization and 18F-radiolabeling of a cyclic peptide (cRGDyK) in an overall peptide synthesis yield of 88% (cRGDyK(NH2)) and subsequent radiolabeling yield of 14 ± 2% (decay corrected, n = 4). This approach is generally applicable to the development of an automated process for the synthesis of cyclic radiolabeled peptides for positron emission tomography (PET).